Status:
COMPLETED
Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.
Lead Sponsor:
Bayer
Conditions:
Vasomotor Symptoms
Eligibility:
FEMALE
45-65 years
Phase:
PHASE3
Brief Summary
The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor symptoms) and uro...
Detailed Description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany. Bayer HealthCare AG, Germany is the sponsor of the trial.
Eligibility Criteria
Inclusion
- Chinese postmenopausal women with moderate to severe vasomotor symptoms
Exclusion
- History of steroid hormone dependent malignant disease
- Known or suspected malignant or premalignant disease
- Current or history of severe heart, liver, renal, psychiatric disease
- Hyperlipemia
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
249 Patients enrolled
Trial Details
Trial ID
NCT00356447
Start Date
May 1 2006
End Date
October 1 2007
Last Update
October 1 2014
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Wuhan, Hubei, China, 430032
2
Nanjing, Jiangsu, China, 210029
3
Jinan, Shandong, China, 250012
4
Beijing, China, 100020